查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1804388

牛皮癬治療市場：2025-2030 年全球預測（按藥物類型、給藥途徑、疾病類型、最終用戶和分銷管道）

Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計牛皮癬治療市場在 2024 年將達到 195.4 億美元，2025 年將達到 211.9 億美元，到 2030 年將達到 322.6 億美元，複合年成長率為 8.71%。

主要市場統計數據
基準年（2024年） 195.4億美元
預計年份（2025年） 211.9億美元
預測年份（2030年） 322.6億美元
複合年成長率（%） 8.71%

在不斷發展的治療方案和影響患者療效的監管動態的背景下理解牛皮癬治療範例

隨著不斷發展的治療平台和法律規範重塑全球患者護理，了解銀屑病治療的複雜性至關重要。乾癬是一種慢性疾病，會導致嚴重的身體不適和社會心理負擔，迫切需要更有效、更有針對性的治療。為此，製藥公司和生技創新者越來越關注有望提高療效、改善安全性並實現個人化治療方法治療流程的治療方法。

突破性生物製藥、數位護理平台、以患者為中心的治療方案和整體療法如何重新定義銀屑病治療的連續性

針對特定免疫途徑的生物製藥開啟了精準醫療的新時代，為此前飽受中度至重度疾病折磨的患者帶來了福音。同時，數位化醫療平台透過遠端醫療諮詢、遠端監測症狀進展和追蹤依從性，使患者能夠更有效地參與治療計劃。以患者為中心的通訊協定整合了穿戴式感測器和行動應用程式，透過促進患者與醫療服務提供者之間的協作，有助於改善治療效果。

評估2025年提案關稅對銀屑病治療供應鏈、定價策略和病患可近性的深遠影響

2025年提案對進口活性藥物原料藥及牛皮癬治療藥物成品徵收關稅，勢必對全球供應鏈帶來壓力。製造商將面臨核心生物製藥製劑成本上漲的風險，這可能導致其對生產地點進行策略性重新評估。因此，一些公司可能會加快對國內製造或其他籌資策略的投資，以降低可能因關稅而導致的成本上漲風險。

識別藥物治療方式、給藥途徑、疾病變體、治療環境和分銷管道中的患者和提供者細分，以推動治療決策

透過多種細分視角，可以更好地理解銀屑病治療現狀，這些視角可以揭示患者和醫護人員的細微行為差異。就藥物類型而言，全身性治療包括生物製藥和照光治療，而外用藥物包括Calcineurin抑制劑、皮質類固醇、類視色素和維生素D類似物。在生物製藥中，IL-17抑制劑、IL-23抑制劑、T細胞抑制劑和TNF-α抑制劑等標靶類別具有差異化的作用機制和安全性。這種精細化細分使相關人員能夠將未滿足的免疫學需求與臨床開發平臺相匹配。

探索美洲、中東和非洲以及亞太地區影響牛皮癬治療可近性和創新的獨特動態

區域動態在塑造全球市場乾癬治療的可及性和創新性方面發揮關鍵作用。在美洲，報銷框架和公私夥伴關係正在推動先進生物製藥的快速應用，這得益於強大的專科藥房網路，該網路為患者提供了支持服務。同時，各州之間的監管協調努力正在縮短新療法的上市時間。

分析影響牛皮癬市場的主要生物製藥和專業公司的策略性舉措、研究夥伴關係和產品創新

領先的生物製藥和專科公司正在部署各種策略性舉措，以保持在銀屑病領域的競爭力。先鋒生物技術公司正在推進下一代 IL-17 和 IL-23 抑制劑的後期臨床試驗，而全球製藥公司則正在擴大其口服小分子產品組合，推出旨在調節細胞內訊號通路的藥物。同時，專科製造商正在投資改良的局部用藥，透過創新的給藥系統和增強的皮膚耐受性來提高患者的依從性。

利用創新藥物開發、病患協作和彈性供應鏈策略來改善牛皮癬治療效果

為了抓住新興市場機會，產業領導者應優先考慮利用精準免疫學和新型標靶途徑的創新藥物開發。從數位依從性平台到遠距諮詢服務，儘早整合病人參與工具，將有助於提高臨床試驗入組率和長期治療依從性。此外，透過雙重籌資策略建立彈性供應鏈框架，可以降低潛在關稅波動和全球市場波動帶來的風險。

為提供可靠的牛皮癬治療見解而採用的綜合混合方法、數據源整合和分析框架的詳細資訊

本分析中提出的全面見解是基於嚴格的混合方法。主要研究包括對關鍵意見領袖、皮膚病學專家和供應鏈專業人士的深入訪談，以獲取有關臨床和業務挑戰的第一手觀點。次要研究整合了同行評審日誌、監管備案文件和專有行業資料庫，以對市場趨勢進行三角測量並檢驗假設驅動的研究。

影響牛皮癬治療和護理未來的關鍵發現、新興機會和戰略重點的摘要

本執行摘要揭示了治療方法、數位參與和市場區隔的變革性變化，這些變化正在重新定義乾癬治療。從提案關稅的策略影響，到患者亞型和區域動態的細微差別，相關人員如今對塑造治療格局的力量有了更清晰的認知。新的商業機會蘊藏在標靶生物製藥創新、數據主導的病患援助平台和彈性供應鏈架構的交匯處。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 專注於透過基因和生物標記分析實現個人化醫療，以最佳化牛皮癬治療效果
  • IL-17 和 IL-23 抑制劑生技藥品在中度至重度乾癬治療通訊協定中的應用日益增多
  • 擴大數位健康平台與遠距皮膚科的整合，實現遠距乾癬管理
  • 生物相似生技藥品的出現將推動成本競爭，擴大患者獲得牛皮癬治療的機會
  • 開發針對蛋白酪氨酸激酶的口服小分子抑制劑作為注射劑的替代品
  • 推出以患者為中心的支援計劃，使用行動應用程式來提高患者對慢性牛皮癬治療的依從性
  • 局部奈米製劑在增強藥物滲透和減少牛皮癬全身副作用的進展
  • 擴大生物製藥與照光治療結合的聯合治療方案，以提高難治性病例的療效
  • 新型PDE4抑制劑已獲得監管機構核准，用於治療輕度至中度乾癬，為非生物製劑治療提供新的選擇
  • 加強真實世界證據研究，評估牛皮癬治療的長期安全性和成本效益

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

第8章 銀屑病治療市場（依藥物類型）

  • 全身性治療
    • 生物製藥
      • IL-17抑制劑
      • IL-23抑制劑
      • T細胞抑制劑
      • TNF-α抑制劑
    • 口服藥物
    • 照光治療
  • 局部治療
    • Calcineurin抑制劑
    • 皮質類固醇
    • 類視色素
    • 維生素 D 類似物

9. 牛皮癬治療市場（依給藥途徑）

  • 注射
  • 口服
  • 局部的

第 10 章 銀屑病治療市場（依疾病類型）

  • 紅皮病型乾癬
  • 水滴狀乾癬
  • 反向型乾癬
  • 斑塊型乾癬
  • 膿皰型乾癬

第 11 章 銀屑病治療市場（依最終用戶分類）

  • 門診手術中心（ASC）
  • 居家照護環境
  • 醫院
  • 專科診所

第 12 章 銀屑病治療市場（按分銷管道）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

13.美洲牛皮癬治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.歐洲、中東和非洲牛皮癬治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區牛皮癬治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Almirall, SA
    • Amgen Inc.
    • Bausch Health Companies Inc.
    • Biogen Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celltrion, Inc.
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • LEO Pharma A/S
    • Lupin Limited
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis AG
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • UCB SA
    • Viatris Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-115D84408DE0

The Psoriasis Treatment Market was valued at USD 19.54 billion in 2024 and is projected to grow to USD 21.19 billion in 2025, with a CAGR of 8.71%, reaching USD 32.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 19.54 billion
Estimated Year [2025] USD 21.19 billion
Forecast Year [2030] USD 32.26 billion
CAGR (%) 8.71%

Understanding the Psoriasis Treatment Paradigm Amid Evolving Therapeutic Options and Regulatory Dynamics Shaping Patient Outcomes

Understanding the complexities of psoriasis treatment is essential as evolving therapeutic platforms and regulatory frameworks reshape patient care worldwide. Chronic in nature, psoriasis imposes substantial physical discomfort and psychosocial burdens, prompting an urgent need for more effective, targeted interventions. In response, pharmaceutical and biotechnology innovators have intensified their focus on next-generation modalities that promise enhanced efficacy, improved safety profiles, and personalized treatment algorithms.

Moreover, intricate reimbursement landscapes and heightened patient expectations are driving stakeholders to reassess traditional care paradigms. Health systems seek integrated approaches that balance clinical outcomes with cost containment, while patients demand modalities that align with their lifestyles and long-term wellness goals. Consequently, a nuanced understanding of current market dynamics lays the foundation for stakeholders to identify areas of unmet need, anticipate regulatory shifts, and craft strategies that deliver sustainable value in the psoriasis treatment continuum.

How Breakthrough Biologics, Digital Care Platforms, Patient-Centric Protocols, and Holistic Approaches Are Redefining the Psoriasis Care Continuum

Breakthrough biologics targeting specific immune pathways have ushered in a new era of precision therapy, offering relief for patients who previously struggled with moderate to severe disease. At the same time, digital care platforms are empowering individuals to engage with treatment plans more effectively through telemedicine consultations, remote monitoring of symptom progression, and adherence tracking. Patient-centric protocols, which integrate wearable sensors and mobile applications, contribute to improved outcomes by fostering collaboration between patients and providers.

Meanwhile, holistic approaches that consider comorbidities such as arthritis, cardiovascular conditions, and mental health are gaining traction, ensuring that treatment regimens address the multifaceted nature of the disease. Consequently, the convergence of targeted biologics, advanced digital tools, and comprehensive clinical frameworks is redefining the psoriasis care continuum, setting new standards for efficacy, convenience, and long-term disease management.

Assessing the Far-Reaching Effects of Proposed 2025 Tariff Structures on Psoriasis Therapies Supply Chains, Pricing Strategies, and Patient Access

In 2025, proposed tariffs on imported active pharmaceutical ingredients and finished psoriasis therapies are poised to exert pressure on global supply chains. Manufacturers may face increased costs for core biologic components, leading to strategic reevaluations of production footprints. Consequently, some organizations could accelerate investments in domestic manufacturing or alternative sourcing strategies to mitigate exposure to potential tariff-related cost increases.

Furthermore, pricing strategies will likely evolve as payers and providers negotiate contracts that reflect shifting cost structures. In parallel, patient access programs and co-pay assistance initiatives may expand to preserve adherence among individuals reliant on costly biologics. Therefore, understanding the cumulative implications of these tariff proposals is critical for companies aiming to safeguard supply continuity, optimize pricing models, and maintain equitable access for the psoriasis patient population.

Uncovering Distinct Patient and Provider Segments Across Drug Modalities, Administration Routes, Disease Variants, Care Settings, and Distribution Channels Driving Treatment Decisions

The psoriasis treatment landscape is best understood through multiple segmentation lenses that illuminate nuanced patient and provider behaviors. When examining drug type, systemic treatments encompass biologics, oral medications, and phototherapy, while topical applications include calcineurin inhibitors, corticosteroids, retinoids, and vitamin D analogues. Within biologics, targeted classes such as IL-17 inhibitors, IL-23 inhibitors, T-cell inhibitors, and TNF-alpha inhibitors offer differentiated mechanisms of action and safety profiles. This granularity enables stakeholders to align clinical development pipelines with unmet immunological needs.

Analysis of administration routes reveals critical trade-offs between injectable, oral, and topical therapies. Injectable formulations often deliver potent systemic control but have higher complexity in patient administration and monitoring. Orally administered agents confer ease of use but must address first-pass metabolism and potential drug-drug interactions. Topical therapies remain fundamental for localized disease management, demanding formulations that optimize skin penetration and minimize irritation.

Disease type segmentation further sharpens market understanding by distinguishing between erythrodermic psoriasis, guttate psoriasis, inverse psoriasis, plaque psoriasis, and pustular psoriasis. Each subtype presents unique clinical manifestations, necessitating tailored therapeutic approaches and clinical trial designs. Additionally, end-user environments ranging from ambulatory surgical centers and homecare settings to hospitals and specialty clinics dictate distinct service delivery models and reimbursement considerations. Finally, distribution channel insights differentiate between offline pathways-hospital pharmacies and retail pharmacies-and online platforms, shaping omnichannel strategies that maximize patient reach and supply chain efficiency.

Exploring Unique Dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific Regions Influencing Psoriasis Treatment Accessibility and Innovation

Regional dynamics play a pivotal role in shaping psoriasis treatment accessibility and innovation across global markets. In the Americas, reimbursement frameworks and private-public partnerships have fostered rapid adoption of advanced biologics, supported by robust specialty pharmacy networks that facilitate patient support services. Meanwhile regulatory harmonization efforts across states are reducing time to market for novel therapies.

In Europe, Middle East & Africa, market heterogeneity is pronounced, with Western European nations benefiting from streamlined approval pathways and patient registries, while emerging economies in the Middle East and Africa face challenges related to infrastructure, diagnostic capacity, and healthcare funding. However, public health initiatives and international collaborations are gradually expanding access to both systemic and topical treatments, laying the groundwork for future growth.

Within Asia-Pacific, dynamic innovation hubs are emerging alongside established markets. Japan and Australia continue to invest heavily in biologic research and development, whereas Southeast Asian countries are rapidly scaling generic and biosimilar production to enhance affordability. Across the region, digital health adoption is accelerating, enabling remote patient monitoring and education programs that bridge gaps in specialist care delivery.

Analyzing Strategic Initiatives, Research Partnerships, and Product Innovations from Leading Biotech and Specialty Firms Shaping the Psoriasis Market

Leading biopharmaceutical and specialty firms are deploying a variety of strategic initiatives to maintain competitive positioning within the psoriasis arena. Biotech pioneers are advancing next-generation IL-17 and IL-23 inhibitors through late-stage clinical trials, while global pharmaceutical companies are expanding their oral small molecule portfolios with agents designed to modulate intracellular signaling pathways. Concurrently, specialty manufacturers are investing in reformulated topical therapies that improve patient adherence through novel delivery systems and enhanced skin tolerability.

Research partnerships between industry leaders and academic centers are accelerating the translation of biomarker discoveries into therapeutic candidates, particularly in the area of personalized medicine. Meanwhile, collaborations with contract manufacturing organizations are enabling scalable biologics production, thereby reducing time to market and enhancing supply chain resilience. In addition, strategic acquisitions and licensing deals are broadening product pipelines, ensuring that companies can address the full spectrum of disease severity and subtype variations.

Leveraging Innovative Drug Development, Collaborative Patient Engagement, and Resilient Supply Chain Strategies to Enhance Psoriasis Care Outcomes

To capitalize on evolving market opportunities, industry leaders should prioritize innovative drug development that leverages precision immunology and novel target pathways. Early integration of patient engagement tools-ranging from digital adherence platforms to remote consultation services-will enhance clinical trial enrollment and long-term treatment adherence. Additionally, establishing resilient supply chain frameworks with dual sourcing strategies can mitigate risks associated with potential tariff fluctuations and global disruptions.

Furthermore, forging multi-stakeholder collaborations with payers, patient advocacy groups, and regulatory bodies can streamline approval processes and foster transparent pricing dialogues. Investing in real-world evidence generation will also provide a stronger evidentiary basis for demonstrating long-term value, ultimately facilitating formulary inclusion and reimbursement approval. By embedding these recommendations within core strategic plans, companies can achieve sustainable growth and deliver superior patient outcomes in the psoriasis treatment landscape.

Detailing the Comprehensive Mixed-Methods Approach, Data Sources Integration, and Analytical Frameworks Employed to Deliver Robust Psoriasis Treatment Insights

A rigorous mixed-methods approach underpins the comprehensive insights presented in this analysis. Primary research consisted of in-depth interviews with key opinion leaders, dermatology specialists, and supply chain experts to capture firsthand perspectives on clinical and operational challenges. Secondary research integrated peer-reviewed journals, regulatory filings, and proprietary industry databases to triangulate market trends and validate hypothesis-driven inquiries.

Quantitative data was subjected to statistical validation techniques, ensuring the reliability of segmentation and regional models. Qualitative insights were coded thematically to uncover emerging patterns in therapeutic adoption, patient behavior, and competitive dynamics. Finally, synthesis workshops with cross-functional teams refined the analytical frameworks and stress-tested strategic scenarios. This multi-layered methodology ensures that the findings are both robust and actionable for decision-makers across the psoriasis treatment ecosystem.

Summarizing Key Findings, Emerging Opportunities, and Strategic Imperatives That Will Shape the Future of Psoriasis Treatment and Care Delivery

This executive summary has illuminated transformative shifts in therapeutic modalities, digital engagement, and market segmentation that are redefining psoriasis care. From the strategic implications of proposed tariffs to the nuanced differentiation of patient subtypes and regional dynamics, stakeholders now have a consolidated view of the forces shaping the treatment landscape. Emerging opportunities lie at the intersection of targeted biologic innovation, data-driven patient support platforms, and resilient supply chain architectures.

In closing, strategic imperatives include prioritizing precision medicine approaches, deepening cross-sector collaborations, and continuously adapting to regulatory evolutions. By aligning scientific breakthroughs with patient-centric delivery models and robust commercial frameworks, organizations can secure competitive advantage and advance the standard of care for individuals living with psoriasis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Focus on personalized medicine through genetic and biomarker profiling to optimize psoriasis treatment outcomes
  • 5.2. Growing uptake of IL-17 and IL-23 inhibitor biologics in treatment protocols for moderate to severe psoriasis
  • 5.3. Increasing integration of digital health platforms and teledermatology for remote psoriasis management
  • 5.4. Emergence of biosimilar biologics driving cost competition and expanded patient access to psoriasis therapies
  • 5.5. Development of oral small molecule inhibitors targeting tyrosine kinases as alternative to injectable treatments
  • 5.6. Implementation of patient-centric support programs leveraging mobile apps to improve adherence in chronic psoriasis care
  • 5.7. Advancements in topical nanoformulations to enhance drug penetration and reduce systemic side effects in psoriasis
  • 5.8. Expansion of combination therapy regimens combining biologics with phototherapy for enhanced efficacy in refractory cases
  • 5.9. Regulatory approval of novel PDE4 inhibitors for mild to moderate psoriasis offering new non-biologic options
  • 5.10. Heightened emphasis on real world evidence studies to assess long-term safety and cost effectiveness of psoriasis drugs

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Psoriasis Treatment Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Systemic Treatments
    • 8.2.1. Biologics
      • 8.2.1.1. IL-17 Inhibitors
      • 8.2.1.2. IL-23 Inhibitors
      • 8.2.1.3. T-cell Inhibitors
      • 8.2.1.4. TNF-alpha Inhibitors
    • 8.2.2. Oral Medications
    • 8.2.3. Phototherapy
  • 8.3. Topical Treatments
    • 8.3.1. Calcineurin Inhibitors
    • 8.3.2. Corticosteroids
    • 8.3.3. Retinoids
    • 8.3.4. Vitamin D Analogues

9. Psoriasis Treatment Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Psoriasis Treatment Market, by Disease Type

  • 10.1. Introduction
  • 10.2. Erythrodermic Psoriasis
  • 10.3. Guttate Psoriasis
  • 10.4. Inverse Psoriasis
  • 10.5. Plaque Psoriasis
  • 10.6. Pustular Psoriasis

11. Psoriasis Treatment Market, by End-User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers (ASCs)
  • 11.3. Homecare Settings
  • 11.4. Hospitals
  • 11.5. Specialty Clinics

12. Psoriasis Treatment Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Online

13. Americas Psoriasis Treatment Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Psoriasis Treatment Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Psoriasis Treatment Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Almirall, S.A.
    • 16.3.3. Amgen Inc.
    • 16.3.4. Bausch Health Companies Inc.
    • 16.3.5. Biogen Inc.
    • 16.3.6. Boehringer Ingelheim GmbH
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Celltrion, Inc.
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. Fresenius Kabi AG
    • 16.3.11. GlaxoSmithKline plc
    • 16.3.12. Johnson & Johnson Services, Inc.
    • 16.3.13. LEO Pharma A/S
    • 16.3.14. Lupin Limited
    • 16.3.15. Merck & Co., Inc.
    • 16.3.16. Mitsubishi Tanabe Pharma Corporation
    • 16.3.17. Novartis AG
    • 16.3.18. Pfizer Inc.
    • 16.3.19. Samsung Bioepis Co., Ltd.
    • 16.3.20. Sanofi S.A.
    • 16.3.21. Sun Pharmaceutical Industries Ltd.
    • 16.3.22. Takeda Pharmaceutical Company Limited
    • 16.3.23. UCB S.A.
    • 16.3.24. Viatris Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. PSORIASIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. PSORIASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. PSORIASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. PSORIASIS TREATMENT MARKET: RESEARCHAI
  • FIGURE 26. PSORIASIS TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. PSORIASIS TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 28. PSORIASIS TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. PSORIASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 179. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 183. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 184. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 235. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 239. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 240. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 253. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 257. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 258. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 271. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 275. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 289. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 293. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 294. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 307. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 311. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 312. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 323. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 331. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 333. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 335. UNI